11thestate Posted - 3 days ago

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over allegations related to the issues with FDA approval of its cancer drug. Even if you missed the deadline, if you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

Elisabeth0Mercado Posted - 6 days ago

$YMAB $ATXS MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

PenkeTrading Posted - 6 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Y mAbs Therapeutics. Is that bullish or bearish? $YMAB #RsiOversold #NASDAQ

11thestate Posted - 1 week ago

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over allegations related to the issues with FDA approval of its cancer drug. Even if you missed the deadline, if you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

DonCorleone77 Posted - 1 week ago

$YMAB Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M Backs FY24: Anticipated Operating Expenses expected to remain between $115 million and $120 million; Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.

DonCorleone77 Posted - 1 week ago

$YMAB Y-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c) Reports Q3 revenue $18.5M, consensus $23.26M. "The third quarter of this year was one of continued focus and execution across our DANYELZA commercial business and our novel SADA PRIT radiopharmaceutical platform development pipeline," said Michael Rossi, President and Chief Executive Officer. "Physician usage of DANYELZA in the U.S. continues to remain very strong for patients with relapsed/refractory high-risk neuroblastoma. In addition, we continue to drive ex-U.S. market expansion with our new exclusive license and distribution agreement with Nobelpharma in Japan and the launch of our named patient program in Turkey. From a SADA PRIT pipeline standpoint, we expect to complete Part A of our GD2-SADA Phase 1 trial this year and present that data in the first quarter of next year."

Doozio Posted - 2 weeks ago

$YMAB ⛈️ is here in da FUTUre of 🧠⏰ which is NOW during 🧠⏰♾️

11thestate Posted - 2 weeks ago

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over allegations related to the issues with FDA approval of its cancer drug. Even if you missed the deadline, if you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

Doozio Posted - 2 weeks ago

$YMAB as long as no faaatch 💣 lands https://youtu.be/5P_bnP_yn_E?si=2FN-5TQ0sVkMFvEu

11thestate Posted - 10/29/24

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over allegations related to the issues with FDA approval of its cancer drug. Even if you missed the deadline, if you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

Quantumup Posted - 10/27/24

$SWTX, $TGTX, $VIR, $XNCR, $YMAB

G101SPM Posted - 10/25/24

CORRECTION AS TO REVISIT PURCHASE DATE $YMAB $14.64 bid. *DAC (dollar average cost after partial sale at a profit) ^^ $5.25 . EXIT $26.00. BRIEF: Today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. * Click SEARCH (magnifying glass) icon on our landing page to review the postings. ^^ Aug 16, 2023 3:14 PM $YMAB $5.25 ... BUY/REVISIT with + SPM 81.04 TAG. EXIT $11.00.

G101SPM Posted - 10/25/24

$YMAB $14.64 bid. *DAC (dollar average cost after partial sale at a profit) $5.25 (4.12.24). EXIT $26.00. BRIEF: Today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.

Shlobby Posted - 10/24/24

$YMAB this one faked me out today. Alert reset

11thestate Posted - 10/22/24

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over allegations related to the issues with FDA approval of its cancer drug. Even if you missed the deadline, if you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

crabhunter Posted - 1 month ago

$ADVM $STOK, $YMAB https://schrts.co/nXRBJipp

Quantumup Posted - 1 month ago

BofA 3Q24 SMID #Biotech earnings preview: $DAWN $SWTX CRSP in focus: $DAWN (Buy/$24): Ojemda launch, pivotal trial focus: $SWTX (Buy/$58): Ogsiveo should recover after soft early Q3: Additional Commercial-Stage Companies Also Mentioned NVAX, $KRYS, $TGTX, AGIO, and $YMAB

11thestate Posted - 1 month ago

$YMAB is now accepting claims for a $19.65M settlement and is paying investors over claims related to the issues with FDA approval of its cancer drug. If you bought between October 06, 2020, and October 28, 2022, you still can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

Doozio Posted - 1 month ago

$ymab NOW it’s 🧠⏰♾️

Doozio Posted - 1 month ago

$YMAB 👀 whUt YO saying da FUTUre of 🧠⏰ is NOW $dogz it’s 🧠⏰♾️

11thestate Posted - 1 month ago

$YMAB has settled with $YMAB investors over claims related to the issues with FDA approval of its cancer drug. The deadline is October 07, 2024. If you bought between October 06, 2020, and October 28, 2022, you can file for a payment here: https://11thestate.com/cases/ymabs-investor-settlement

Night_Owl_Biotech Posted - 1 month ago

The attachment graphs the share price of UroGen $URGN since 5/31/24. UroGen published updated Phase 3 data of its UGN-102 candidate on 6/13/24. URGN shares then surged to peak intra-day at $20.70 (up 63%) before closing at $19.20/share (up 51%). A few days later URGN closed a $108MM stock offering with, we assume, accredited investors at $17.50/share. At $12.36/share (10/3/24 at 11:30 AM), URGN shares are now off 29% from the date investors purchased $108MM of URGN stock at $17.50 a share. URGN submitted its UGN-102 NDA on 8/14/24. URGN estimates the market for its UGN-102 candidate in NMIBC to be 10X higher than Jelmyto's market. Jelmyto does ~$80MM year. URGN & $YMAB have, more or less, the same valuation & FDA approved annual product revenue profile (though URGN has large debts). As far as we know, YMAB does not have a near term candidate for approval like URGN. We could be wrong about YMAB. This is not investment advice. $XBI $IBRX $MRK

Doozio Posted - 1 month ago

$YMAB Thursday 🐑 🎁 in 🧠⏰

Shlobby Posted - 1 month ago

$YMAB failed me

Shlobby Posted - 1 month ago

$YMAB took a stab toward eod on the break out

11thestate Posted - 09/23/24

$YMAB has settled $19.6M with $YMAB investors due to the claims related to the issues with FDA approval of its cancer drug. The filing deadline is October 07, 2024. If you bought between October 06, 2020, and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

insiderbuyingselling Posted - 2 months ago

$YMAB new insider selling: 95000 shares. http://insiderbuyingselling.com/?t=YMAB

Night_Owl_Biotech Posted - 2 months ago

Attached is a table of all 35 new commercial-stage oncology focused biopharmas since 1/1/2019 (those that received their first FDA approved therapy since 1/1/2019. The table notes the share prices of all 35 as of 2 days after receiving FDA approval versus today (or the M&A price for those acquired). 7 of the 35 were acquired within 2 years of approval at meaningfully higher prices. 3 were acquired at lower prices (but all had reasons why). 2 no longer trade. Of the 23 that are still independent, 16 or 70% trade at a lower share price today than when approved while 7 or 30% trade higher. Follow us as we will post the same data points for the 61 bios that received their first approval since 1/1/2011. This is not investment advice but it appears reasonably clear shareholders generally do much better in M&A & the sooner the better after approval. Much more analysis to come. $YMAB $ADCT $MGNX $BGNE $LEGN

11thestate Posted - 2 months ago

$YMAB is now accepting claims for a $19.65M settlement it is paying to investors over claims related to the issues with FDA approval of its cancer drug. The filing deadline is October 07, 2024. If you bought between October 06, 2020 and October 28, 2022, you can file for payment here: https://11thestate.com/cases/ymabs-investor-settlement

G101SPM Posted - 2 months ago

$YMAB $14.11 bid. *DAC (dollar average cost) $5.25. EXIT $26.00. UPDATE: Today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 -- 7, 2024, at the American Academy of Cancer Research ("AACR") Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.